InvestorsHub Logo
Followers 14
Posts 737
Boards Moderated 0
Alias Born 09/13/2013

Re: None

Friday, 06/19/2015 6:54:22 AM

Friday, June 19, 2015 6:54:22 AM

Post# of 50661
OXIS International, Inc. (OTCMKTS:OXIS) has appointed Dr. Stephen M. Chang to its scientific advisory board and has also filed a patent for its lead compound OXS-4235. The drug is essentially a p62 inhibitor, which demonstrates inhibition of myeloma cell growth, without toxicity to bone marrow stromal cells. The product is expected to target the cancer formation in white blood cells.

http://www.journaltranscript.com/2015/06/oxis-international-inc-otcmktsoxis-makes-progress-towards-gaining-p-62-patent/